NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Strong-Buy at HC Wainwright

NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q3 2026 earnings at ($0.59) EPS.

A number of other research analysts have also commented on the company. The Goldman Sachs Group raised their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Leerink Partners reissued an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $34.63 on Thursday. The firm has a market capitalization of $3.93 billion, a PE ratio of -20.02 and a beta of 0.06. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $42.00. The business’s fifty day moving average price is $34.00 and its two-hundred day moving average price is $32.45.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 25.99%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Equities research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00. Following the completion of the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $774,425.40. This trade represents a 57.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 298,647 shares of company stock valued at $10,236,050 in the last quarter. Insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of NAMS. Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $85,000. XTX Topco Ltd lifted its position in shares of NewAmsterdam Pharma by 1,714.1% in the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock valued at $4,823,000 after acquiring an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in NewAmsterdam Pharma by 32.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock worth $251,000 after purchasing an additional 1,731 shares during the period. Twinbeech Capital LP purchased a new position in NewAmsterdam Pharma during the 4th quarter worth approximately $961,000. Finally, Millennium Management LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $8,931,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.